

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number  
WO 01/79174 A1

(51) International Patent Classification<sup>7</sup>: C07D 213/89

(21) International Application Number: PCT/HU01/00046

(22) International Filing Date: 17 April 2001 (17.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P 0001583 18 April 2000 (18.04.2000) HU

(71) Applicant (for all designated States except US): BIOREX  
KUTATÓ ÉS FEJLESZTŐ [HU/HU]; Szabadságpuszta,  
H-8200 Veszprém (HU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ÜRÖGDI, László [HU/HU]; Teleki u. 80, H-1184 Budapest (HU). JEGESNÉ CSÁKAI, Zita [HU/HU]; Pető ltp. B/19, H-6090 Kunszentmiklós (HU). GRUBER, Lajos [HU/HU]; Cserje u. 18 I/2, H-1025 Budapest (HU). ÖTVÖS, László [HU/HU]; Boróka u. 13 II/10, H-1025 Budapest (HU). TÓTH, József [HU/HU]; Alsó Törökvesz út 10, H-1022 Budapest (HU). TÖMÖSKÖZI, István [HU/HU]; Szépvölgyi út 106, H-1025 Budapest (HU). SZAKÁCSNÉ SCHMIDT, Anikó [HU/HU]; Alkotmány

u. 7. I/3, H-8200 Veszprém (HU). REIDER, Ferencné [HU/HU]; Sólai u. 2. II/9, H-8200 Veszprém (HU). SCHNEIDERNÉ BARLAY, Mária [HU/HU]; Ady Endre út 67, H-8200 Veszprém (HU).

(74) Agent: S.B.G. AND K. PATENT AND LAW OFFICES;  
Andrássy út 113, H-1062 Budapest (HU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PYRIDINE-1-OXIDE DERIVATIVE, AND PROCESS FOR ITS TRANSFORMATION INTO PHARMACEUTICALLY EFFECTIVE COMPOUNDS

(57) Abstract: The invention relates to N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers. (R)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and (S)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine. Furthermore, the invention relates to the preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxyimidoyle chloride, which may be used as an active ingredient of medicaments, and the preparation of the optically active enantiomers of this compound using the compounds of the invention as intermediate substances.

WO 01/79174 A1

**A-Pyridine-1-Oxide Derivative, and Process for its Transformation into  
Pharmaceutically Effective Compounds**

5

**TECHNICAL FIELD**

The invention relates to a new pyridine-1-oxide-3-carboxamide derivative, which may be used as intermediate in the production of the active ingredient of pharmaceutical products for the treatment of diabetic complications. Namely, the invention relates to the compound N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamide and its optically active enantiomers, (R)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamide and (S)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamide. Furthermore, the invention relates to the preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, which may be used as an active ingredient of medicaments, and the preparation of the optically active enantiomers of this compound using the compounds of the invention as intermediate substances.

20 **BACKGROUND ART**

N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride, along with several related compounds, is known from WO 97/16439 as an effective agent suitable for increasing the chaperone expression of cells. In this publication, the compound is defined as a novel compound, and the N-oxide

derivatives of the compound are also claimed, but there is no specific mention of the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, and its preparation process is not described either.

N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride is disclosed and claimed as a novel compound in WO 00/50403, and its production process is described there as well. The compound is produced by the oxidation of the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride. In the course of oxidation with peracids, the bis-N-oxide derivative oxidized on the N-atoms of both the piperidine ring and the pyridine ring, or the piperidine-N-oxide derivative are formed preferentially, and therefore the oxidation with peracid must be performed in the presence of a strong acid to ensure the dominance of the formation of the pyridine-N-oxide derivative in the course of the oxidation process. The yield of this process, however, is not satisfactory. The optically active enantiomers of the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride are also described in WO 00/50403. They are prepared in a way similar to the preparation of the raceme compound using the suitable optically active starting substances.

Considering the fact that the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and its optically active enantiomers are not only useful in the treatment of diabetic complications, primarily retinopathy, neuropathy and nephropathy, but simultaneously reduce chronic insulin resistance, these compounds are valuable active ingredients in pharmaceutical products. However, in order for these compounds to be useful

in the pharmaceutical industry, an easier process is necessary for their production.

#### DISCLOSURE OF INVENTION

5        We have found that N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboxamidine of formula (I), which is a new compound, is useful as intermediate for making possible the simple production of N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride in high purity and in a high yield.

10        Based on this observation, the present invention relates to the N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboxamidine, and its acid addition salts. The invention also relates to the optically active enantiomers of the aforementioned compound, the (R)-(-)-N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboxamidine and the (S)-(+)-N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboxamidine, and the acid addition  
15        salts of these compounds.

Hereafter, "optically active enantiomer" refers to a compound whose optical purity is at least 80%, preferably at least 90%, most preferably at least 96%, that is, the compound contains at least this mass ratio of the specified  
20        optically active enantiomer. "Acid addition salts" refers to salts produced from the compounds with mineral or organic salts, by the known process.

As mentioned above, the compounds of the invention may be used as intermediates in the production of N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride. Therefore, the invention relates to the

use of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers in the preparation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride-and-its-optically-active enantiomers.

5       The compound N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carbox-amidine of the invention is preferably prepared by the following method.

3-cyano-pyridine is used as a starting compound, and the 3-cyano-pyridine-1-oxide of formula (II), which is known from the literature [J. Chem. Soc. 3680 (1959)], can be produced by oxidation. A peracid is used as oxidant, preferably m-chloro-perbenzoic acid. The thus obtained product may be purified by crystallization, but the raw product may also be used in the next step of the synthesis.

By reacting the 3-cyano-pyridine-1-oxide of formula (II) with hydroxylamine, 3-pyridine-amidoxim-1-oxide of formula (III) is produced. The reaction is performed in a suitable aqueous solution, at room temperature, by reacting 3-cyano-pyridine-1-oxide with hydroxylamine, added in excess and liberated in water *in situ* from its hydrochloride salt with sodium bicarbonate. The product precipitates, therefore it can easily be isolated and purified by crystallization.

N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine of formula (I) is prepared from the 3-pyridine-amidoxim-1-oxide of formula (III), by reacting the compound with a reactive 3-(1-piperidino)-2-hydroxy-propane derivative. As reagent, a 1-halo- or 1,2-epoxy-derivative may be used, but

preferably a cyclic derivative, a halide of 2-hydroxy-4-azoniaspiro[3,5]nonane should be used as reagent. The most preferable reagent is the 2-hydroxy-4-  
-azoniaspiro[3,5]nonane-chloride-of-formula-(IV). The reaction is performed in an  
alkaline medium, using a suitable alcohol, preferably an alkanol of 1-3 carbon  
5 atoms, more preferably ethanol as solvent. The reagents may be added in any  
order. Preferably, the reactive 3-(1-piperidino)-2-hydroxy-propane derivative is  
applied in a slight excess. The reaction is performed at an elevated  
temperature, preferably at the boiling-point of the solvent.

The thus obtained compound of formula (I) is either isolated as a base  
10 and used as intermediate in the preparation of the biologically effective N-[2-  
hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, or  
the compound is transformed into an acid addition salt with a mineral or organic  
acid. Thus mono- or dihydrochloride, maleate, or any other acid addition salt  
may be prepared which are suitable for the use of the compound as  
15 intermediate in the preparation of the above mentioned end product. However, it  
is not necessary to isolate the N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-  
1-oxide-3-carboximidine to be used as intermediate. The next step in the  
synthesis of N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-  
carboximidoyl chloride may be performed without the isolation of the compound  
20 of formula (I) as well.

When preparing of an optically active product is desired, the compound  
of formula (I), prior to the transformation, can be resolved by reacting it with an  
optically active acid suitable for the formation of a diastereomer salt pair, by the  
well known methods of resolution. When the salt of the required optical purity is

obtained, the optically active base may be liberated from it. Thereafter, if needed, an acid addition salt may be produced from the base with a mineral or organic acid. ~~Either the base or the salt may then be used for the next step of~~ the process of the invention.

5        According to the invention, N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine of formula (I) is transformed into N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride by diazotation in the presence of hydrochloric acid. The diazotation is performed by the usual method, at a temperature of between -5°C and 0°C, with the slow  
10       addition of an alkali-nitrite, preferably of sodium-nitrite. In the presence of hydrochloric acid, the thus obtained diazonium salt decomposes at the temperature of the diazotation into N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride of formula (V). Then the reaction mixture is alkalified, while cooling, and the product is isolated in the form of a  
15       base by the usual method. The obtained base may be further purified if needed, or transformed into an acid addition salt with a mineral or organic acid. Preferably, maleate or citrate is formed from the compound of formula (V), but it may also be transformed into hydrochloride, dihydrochloride or any pharmaceutically acceptable acid addition salt.

20       The required optically active enantiomers of the N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride of formula (V) prepared by diazotation are prepared by resolution from the raceme compound. The resolution is again performed by the formation of a diastereomer salt pair,

preferably with dibenzoyl-tartaric acid, using its suitable optically active form for the salt formation.

~~If the above described diazotation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidine of formula (I) is performed on an~~  
5 optically active enantiomer, the enantiomer of the N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride of formula (V) of opposite rotation is formed, of satisfactory optical purity. Therefore, according to another version of the process of the invention, the optically active N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride of formula (V) is  
10 prepared by performing the above described diazotation on the suitable optically active enantiomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidine of formula (I). The thus obtained base may be further purified if needed, or an acid addition salt may be formed with a mineral or organic acid.

15 The advantage of the invention is that, by the use of the compound of formula (I) of the invention as intermediate, it makes possible the production of highly pure N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, which has valuable biological effects. Contrary to the process described in WO 00/50403 mentioned in the introduction, in which this  
20 compound is prepared by the oxidation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride, in this current process the appearance of the products of competitive reactions need not be taken into account. By the process of the invention, the base form of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride is obtained in



high purity. Up to this point, this was only possible by lengthy purification, or by liberation of the base from the maleate salt.

A further advantage of the invention is that the N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboxamide of the invention may be produced by the merge of the steps described above and illustrated in the following examples in greater detail, without the isolation and/or purification of each intermediate product, still obtaining satisfactory purity. This way, the production of the intermediate N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboxamide becomes possible in the circumstances of pharmaceutical production, which makes possible the industrial production of the biologically effective N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

#### BEST MODE OF CARRYING OUT THE INVENTION

The invention is illustrated by the following examples.

##### Example 1.

The preparation of 3-cyano-pyridine-1-oxide (compound of formula II)

86g (0.378 mol) of 76% m-chloro perbenzoic acid is dissolved in 730ml of dichloro-methane at 20-25°C, and 220 ml of the solution of 38.3g (0.378 mol) of 3-cyano-pyridine in dichloro-methane is added at 20-28°C. The reaction mixture is stirred at 20-24°C for 24 hours. At the end of the reaction, the solvent is evaporated. The evaporation residue is digested in 430ml of methyl *tert*-butyl ether, the precipitate is filtered, washed and dried. 59g of raw product is obtained.

By recrystallizing the raw product twice from hot ethanol, 36.6g (80%) of pure 3-cyano-pyridine-1-oxide is obtained, which melts at 174-176.5°C (literature: 174-175°C; J. Chem. Soc. 3680 (1959)).

5           Example 2.

The preparation of 3-pyridine-amidoxim-1-oxide (compound of formula III)

25.41g (0.366 mol) of hydroxylamine hydrochloride and 36.6g (0.305 mol) of 3-cyano-pyridine-1-oxide are dissolved in 540ml of water, then 30.72g  
10 (0.366 mol) of sodium-hydrogen carbonate is added in small portions. The reaction mixture is stirred for 2 hours at 20-25°C. The suspension is filtered, the precipitate is washed with water, dried, and recrystallized from a 9:1 mixture of methanol and water. The precipitate separating on cooling is filtered, washed and dried. 37.3g (80%) of the title compound is obtained, which melts at 212-  
15 215°C while decomposing.

IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3407, 3337, 2840, 1660, 1470, 1429, 1397, 1227, 947, 925, 808, 792.

Example 3.

a) The preparation of N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-  
20 pyridine-1-oxide 3-carboxamidine (compound of formula I)

13.5g (0.34 mol) of sodium-hydroxide is dissolved in 35ml of water, and the solution is cooled to 10°C. 60.75g (0.34 mol) of 2-hydroxy-4-azoniaspiro[3,5]nonane chloride is added, and the reaction mixture is stirred for 40 minutes at 5-10°C. 540ml of ethanol and 40.5g (0.26 mol) 3-pyridine-

amidoxim-1-oxide are added. The reaction mixture is heated for 2 hours under a reflux condenser. The solution is cooled, the separated sodium chloride is filtered, washed with 100ml of ethanol, and then the solvent is evaporated off. The evaporation residue is digested with diethyl-ether, the precipitate  
 5 separated in the cooler is filtered, washed with ether, dried, and crystallized hot from isopropanol. 47.4g (62%) of the title compound is obtained, which melts at 130-132.5°C.

IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3397, 3189, 2928, 1647, 1610, 1570, 1505, 1425, 1247, 1226, 1033, 942, 901, 782, 662, 531.

10           b) The preparation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine monohydrochloride

The obtained base of formula (I) is dissolved in ethanol, and 1 equivalent of ethanolic hydrochloric acid solution is added. The solution is evaporated, and the residue is digested with isopropanol. The separated salt is filtered, washed  
 15 and dried. N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine monohydrochloride is obtained. Melting point: 142-144.5°C.

$^1\text{H-NMR}$ : (Solvent: DMSO; referent: DMSO; MHz: 75.4)  $\delta$  [ppm]:  
 9.65 (bs, 1H,  $\text{NH}^+$ ); 8.42 (s, 1H, 2-pyridine); 8.22 (d, 1H, 6-pyridine); 7.58 (d, 1H, 4-pyridine); 7.42 (t, 1H, 5-pyridine); 6.50 (s, 2H,  $\text{NH}_2$ ); 5.72 (d, 1H, OH); 4.24  
 20 (bm, 1H, OCH); 3.86 (m, 2H,  $\text{NOCH}_2$ ); 3.42 (m, 2H, 2 x  $\text{NCH}_{\text{eq}}$ ); 3.18 (m, 2H,  $\text{NCH}_2$ ); 2.92 (m, 2H, 2 x  $\text{NCH}_{\text{ax}}$ ); 1.36-1.8 (m, 6H, 3-, 4- and 5-piperidine).

$^{13}\text{C-NMR}$ : (Solvent: DMSO; Referent: DMSO; MHz: 75.4)  $\square$  [ppm]:  
 148.2 (CNO); 139.2 (2-pyridine); 135.9 (6-pyridine); 131.8 (3-pyridine); 126.3 (5-pyridine); 122.9 (4-pyridine); 74.9 (CHOH); 63.6 ( $\text{NOCH}_2$ ); 58.9 ( $\text{NCH}_2$ ); 53.6

and 51.9 (2C,2 x piperidine NCH<sub>2</sub>); 22.1 (2C,3- and 5-piperidine); 21.2 (4-piperidine).

Cl<sup>-</sup> content According to Mohr (calculated / measured): 10.7 / 10.45.—

5            Example 4.

a)    The preparation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride (Compound of formula V)

The solution of 6.1g (0.088 mol) of sodium nitrite in 40ml of water is added dropwise at -5 - 0°C to the solution of 20g (0.068 mol) of N-[2-hydroxy-3-  
10 (1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine in 110ml of 1M hydrochloric acid cooled to -5°C. The reaction mixture is stirred for 1.5 hours at between -5°C and 0°C, and then, by intense cooling (t < 7°C), the mixture is alkalified with a 7M NaOH solution to pH = 10.5-11.5. The solution is extracted three times with 180ml of dichloro-methane, the organic phases are pooled,  
15 dried on anhydrous MgSO<sub>4</sub>, filtered, washed and evaporated. The thus obtained thick oil is digested in 130ml of methyl *tert*-butyl ether. The suspension is refrigerated for 12 hours, the following day the precipitate is filtered, washed and dried. 18g (85%) of the title compound is obtained, which melts at 90-91.5°C.

20 IR:  $\nu$  (KBr, cm<sup>-1</sup>): 3224, 2935, 2800, 2780, 1570, 1555, 1428, 1301, 1290, 1200, 1100, 1054, 1044, 1023, 1015, 995, 845, 827, 785, 710, 665.

b)    The preparation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate

50g of the base prepared as described above is dissolved in 50ml of acetone, and an equivalent amount (1.85g) of maleic acid is added to it. The separated precipitate is filtered, washed with acetone and dried. The product is recrystallized from ethanol. 6.0g (87%) of N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate (1:1) is obtained, which melts at 150.5-154.5°C.

<sup>1</sup>H-NMR: (Solvent: DMSO; Referent: DMSO; MHz: 300) □ [ppm]:

8.55 (s, 1H, 2-pyridine); 8.35 (d, 1H, 6-pyridine); 7.68 (d, 1H, 4-pyridine); 7.55 (m, 1H, 5-pyridine); 6.00 (s, 2H, CH=CH); 4.23-4.48 (m, 3H, CH-OH and NOCH<sub>2</sub>); 2.95-3.50 (m, 6H, 3 NCH<sub>2</sub>); 1.20-1.90 (m, 6H, piperidine: 3 CH<sub>2</sub>).

<sup>13</sup>C-NMR: (Solvent: DMSO; Referent: DMSO; MHz: 75.4) □ [ppm]:

167.6 (2C, 2 COOH); 141.0 (2-pyridine), 136.8 (6-pyridine); 136.4 (2C, CH=CH); 133.4 (CCl); 131.9 (3-pyridine); 127.2 (4-pyridine); 123.6 (5-pyridine); 77.9 (NOCH<sub>2</sub>); 63.6 (CH<sub>2</sub>N); 58.3 (CHOH); 52.0-55.0 (2C, piperidine: 2 NCH<sub>2</sub>); 22.6 and 21.7 (3C, piperidine: 3 CH<sub>2</sub>).

c) The preparation of (R,S)-N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine 1-oxide-3-carboximidoyl-chloride monohydrochloride

0.64 g (2.0 mmoles) of (R,S)-N-[2-hydroxy-3-(1-piperidinyloxy)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride base is dissolved in 20 ml of ethylacetate and 0.64 ml of the ethereal solution of 3.2 M hydrochloric acid is added while stirring. A sticky precipitate is formed. After evaporating the solvent, 15 ml of acetone is added and refrigerated overnight. The precipitate is crystallized with the addition of some drops of ethanol, then the white

hygroscopic material is quickly filtered, and dried in a desiccator over phosphorous-pentoxide.

Yield: ——— 0.4 g (56.3 %) —

Melting point: 115-122 °C

5 Cl %(ionic): 11.2 % (theoretical: 10.1 %)

IR (KBr,  $\text{cm}^{-1}$ ): 3240, 3060, 2950, 2860, 2760, 1575, 1550, 1465, 1450, 1431, 1310, 1293, 1240, 1195, 1155, 1120, 1090, 1075, 1045, 1005, 945, 925, 830, 792, 715, 671, 550.

10

#### Example 5.

a) The preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride by the resolution of the raceme compound

15 54g (0.172 mol) of raceme N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride is dissolved in 720ml of dry ethanol. After complete dissolution, 64.7g (0.172 mol) of (-)-dibenzoyl-L-tartaric acid monohydrate is added. After seeding, it is crystallized at room temperature, then the separated precipitate is filtered, washed and dried. The obtained  
20 residue is crystallized twice from dry ethanol. 38g (65%) of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride dibenzoyl-L-tartaric acid salt is obtained.

The thus obtained 38g (0.056 mol) of tartaric acid salt is then added to 230ml of 1M  $\text{K}_2\text{CO}_3$  solution, and the mixture is extracted with 3 x 225ml of

dichloro-methane. The organic phases are pooled, dried on anhydrous  $\text{MgSO}_4$ , treated with charcoal, filtered and evaporated. The compound is obtained in a pure form from the crude base by crystallization with hexane. Yield: 14.0g (80%). Melting point: 91-93°C.

5 IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3181, 2938, 2800, 1575, 1555, 1473 1431, 1350, 1300, 1286, 1251, 1232, 1186, 1162, 1555, 1095, 1055, 1044, 1020, 1011, 963, 928, 908, 899, 850, 831, 803, 700, 670.

$^1\text{H}$ -NMR: (Solvent:  $\text{CDCl}_3$ ; Referent:  $\text{CDCl}_3$ ; MHz:300)  $\delta$  [ppm]:

8.62 (s, 1H, 2-pyridin), 8.20 (d, 1H, 6-pyridine); 7.64 (m, 1H, 4-pyridine); 7.26  
10 (m, 1H, 5-pyridine); 4.24 (d, 2H,  $\text{NOCH}_2$ ); 4.02 (m, 1H, OCH); 2.58 (m, 2H,  $\text{NCH}_2$ ); 2.32 (m, 4H, 2 x piperidine  $\text{NCH}_2$ ); 1.5-1.6 (m, 4H, 3- and 5-piperidine); 1.42 (m, 2H, 4-piperidine).

$^{13}\text{C}$ -NMR: (Solvent:  $\text{CDCl}_3$ ; Referent:  $\text{CDCl}_3$ ; MHz:75.4)  $\delta$ [ppm]:

140.0 (2-pyridine); 137.5 (6-pyridine); 132.7 (CNO); 132.4 (3-pyridine); 125.5 (5-  
15 pyridine); 123.8 (4-pyridine); 78.8 (OCH); 64.9 ( $\text{NOCH}_2$ ); 60.6 ( $\text{NCH}_2$ ); 54.6 (2C, 2x piperidin  $\text{NCH}_2$ ); 26.0 (2C, 3- and 5-piperidine); 24.1 (4-piperidine).

b) The preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate

18.0 g of crude (evaporation residue from the process a/) or isolated  
20 base is dissolved in 62ml of acetone, and then the solution of 6.6 g maleic acid in 46ml of acetone is added. The precipitate separating on cooling is filtered, washed with 10ml of acetone and dried. The precipitate (approx. 23g) is crystallized from 120ml of hot ethanol. The precipitate separating on cooling is filtered, washed and dried.

Yield: 20g (82%)

Melting point: 132.0-133.5°C

Enantiomer ratio: 98/2 (HPLC measurement on a Chiral-AGP-100x4mm column)

5 IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3270 (b); 2935; 2850, 1581; 1484; 1436; 1349; 1293 (s); 1205 (s); 1067; 1047; 999 (s); 865 (s); 830; 800, 682, 558.

The  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectra were the same as those of the raceme compound (Example 4/b).

c) The preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-  
10 pyridine-1-oxide-3-carboximidoyl chloride citrate

2.43g (7.75 mmol) of (+)-R/-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride is dissolved in 15ml of acetone while heating gently, then 5ml of the solution of 1.63g (7.75 mmol) of citric acid in acetone is added. The separating white sticky substance becomes  
15 a powder on the addition of 5ml of methanol. The solution is refrigerated until the following day. The precipitate is filtered, washed with acetone, and dried. 3.99g (98%) of product is obtained.

Melting point: 163-165°C.

$^{13}\text{C}$ -NMR: (Solvent:DMSO/ $\text{CDCl}_3$ ; Referent:  $\text{CDCl}_3$ ; MHz:75.4)  $\delta$  [ppm]:

20 175.2 (COOH); 169.9 (2C, 2 COOH); 138.6 (2-pyridine), 134.7 (4-pyridine); 131.0 (CCI); 129.9 (3-pyridine); 125.0 (6-pyridine); 122.5 (5-pyridine); 76.0(COH); 69.7(CHOH); 62.0 (NOCH<sub>2</sub>); 57.0 (CH<sub>2</sub>N); 51.5 (2C, 2 x piperidine NCH<sub>2</sub>); 42.3(2C,2 x CH<sub>2</sub>); 21.0 (2C, 3- and 5-piperidine CH<sub>2</sub>); 20.0(4-piperidine).



d) The preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride monohydrochloride

0.88 g (2.8 mmoles) of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride base (prepared from its maleate using dichloromethane/10 % aqueous sodium-carbonate solution) is dissolved in 25 ml of ethylacetate and 0.87 ml of the etheric solution of 3.2 M hydrochloric acid is added while stirring.

After evaporating the solvent, 15 ml of acetone is added to the residual sticky oil and crystallized with the addition of some drops of ethanol. The white compound is filtered and washed with acetone and diethyl ether.

Yield: 0.8 g (81.6 %)

Melting point: 127-131 °C

Cl %(ionic): 12.1 % (theoretical: 10.1 %)

IR (KBr, cm<sup>-1</sup>): 3510, 3365, 3120, 3075, 2950, 2930, 2890, 2855, 2725, 2655, 2568, 2527, 1620, 1600, 1562, 1483, 1460, 1428, 1407, 1350, 1335, 1294, 1238, 1197, 1170, 1125, 1072, 1019, 1002, 942, 910, 877, 859, 825, 802, 708, 671, 629, 608, 556, 501.

e) The preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride dihydrochloride

0.65 g (2.0 mmoles) of (R)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride base (prepared from its maleate using dichloromethane/10 % aqueous sodium-carbonate solution) is dissolved

in 25 ml of ethylacetate and 1.4 ml of the etheric solution of 3.2 M hydrochloric acid is added while stirring.

~~After evaporating the solvent, 15 ml of acetone is added to the residual~~  
sticky oil and crystallized with the addition of some drops of ethanol. The white  
5 compound is filtered and washed with cold acetone and diethylether.

Yield: 0.4 g (55.0 %)

Melting point: 160-164 °C

Cl % (ionic): 18.5 % (theoretical: 18.3 %)

IR (KBr, cm<sup>-1</sup>): 3510, 3365, 3120, 3075, 2950, 2930, 2890, 2855, 2725,  
10 2568, 2527, 1620, 1600, 1562, 1483, 1460, 1428, 1407, 1350, 1335, 1294,  
1238, 1197, 1170, 1125, 1072, 1019, 1002, 942, 910, 877, 859, 825, 802, 708,  
671, 629, 608, 556, 501.

#### Example 6.

15 a) The preparation of (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-  
pyridine-1-oxide-3-carboxamidine by the resolution of the raceme compound

1.74g (5.9 mmol) of raceme N-[2-hydroxy-3-(1-piperidiny)-propoxy]-  
pyridine-1-oxide-3-carboxamidine is dissolved in 15ml of ethanol, and then 2.1g  
(5.9 mmol) of +/-dibenzoyl-D-tartaric acid is added to the solution. It is  
20 crystallized at room temperature, the separated salt is filtered, washed with  
ethanol, and dried. The 2.1g product is then crystallized twice from ethanol to  
give 0.33g (17%) of (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-  
oxide-3-carboxamidine diebnzoyl-D-tartaric acid salt (melting point: 156-158°C).

The (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carbox-amidine is liberated from the obtained salt by distribution between 2M  $K_2CO_3$  solution and chloroform, evaporation of the chloroform solution, and isolation with ether. Yield: 0.11g (13%).

5 Melting point: 123-126°C.

IR:  $\nu$  (KBr,  $cm^{-1}$ ): 3398, 3188, 2936, 2800, 1647, 1600, 1560, 1500, 1426, 1245, 1226, 1033, 942, 907, 800, 667.

Rotation:  $[\alpha]_D = +4,5^\circ$  ( $c = 1$ , methanol).

To determine the optical purity of the product, a small sample is transformed into the corresponding chloro compound, (S)-(-)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride by the diazotation process described in example 4/a, and its optical purity is determined by HPLC on a Chiral AGP column. Determined by this method, the optical purity of the product gained by the described resolution process is 96%.

15 b) The preparation of (R)-(-)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine by the resolution of the raceme compound

Following the process described in a), but this time using (-)-dibenzoyl-L-tartaric acid for the resolution, the yield of the obtained dibenzoyl-tartrate salt is 20%, and its melting point is 156.5-158°C. After liberating the base from this, (R)-(-)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine is obtained of optical purity of 96%.

20 Rotation:  $[\alpha]_D = -4,5^\circ$  ( $c = 1$ , methanol).

Its melting point and IR spectrum are the same as those of the other enantiomer.

c) The preparation of (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine monohydrochloride

The (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carbox-amidine base prepared by the example 6/a is dissolved in isopropanol.

5 Equivalent amount of isopropanolic hydrochloric acid solution is added. The crystallized monohydrochloride salt is filtered and dried.

Melting point: 164-165.5°C

IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3400, 3317, 3191, 2948, 2862, 2710, 2690, 2655, 1651, 1562, 1429, 1407, 1308, 1232, 1112, 1052, 1010, 962, 944, 880, 797, 670.

10 d) The preparation of (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine maleate

The maleate salt of the (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine base prepared by example 6/a is prepared by the addition of equivalent maleic acid in an isopropanolic solution.

15 Melting point: 148-150.5°C.

IR:  $\nu$  (KBr,  $\text{cm}^{-1}$ ): 3465, 3381, 3360, 3092, 3058, 2945, 2855, 1651, 1619, 1582, 1561, 1499, 1474, 1459, 1451, 1432, 1318, 1352, 1250, 1230, 1204, 1086, 1035, 1015, 931, 867, 805, 797, 782, 696, 675, 564.

20 Example 7.

The preparation of (S)-(-)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride by diazotation

By diazotation according to the process described in example 4. followed  
by the decomposition of the diazonium salt, 5g of the (S)-(+)-N-[2-hydroxy-3-(1-  
piperidinyI)-propoxy]-pyridine-1-oxide-3-carboxamidine, ~~prepared under~~  
example 6/a by the resolution of N-[2-hydroxy-3-(1-piperidinyI)-propoxy]-  
5 pyridine-1-oxide-3-carboxamidine, is transformed into (S)-(-)-N-[2-hydroxy-3-(1-  
piperidinyI)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride. 4.4g (82%) of  
the product is obtained. The characteristics of the obtained product are the  
same as those given for the other enantiomer in example 5.

The base is reacted with maleic acid by the process given in example 5,  
10 and thus the corresponding maleate salt is obtained, whose characteristics are  
also the same as those given in example 5.

## CLAIMS

1. N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine and its acid addition salts.
- 5 2. (R)-(-)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine and its acid addition salts.
3. (S)-(+)-N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine and its acid addition salts.
4. The use of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine and its optically active enantiomers for the preparation  
10 of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and its optically active enantiomers.
5. Process for the preparation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and its acid addition salts,  
15 comprising:
  - a) the diazotation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine by reacting with an alkali-nitrite in the presence of hydrochloric acid, or
  - b) the diazotation of N-[2-hydroxy-3-(1-piperidiny)-propoxy]-pyridine-1-oxide-3-carboxamidine by reacting with an alkali-nitrite in the presence of  
20 hydrochloric acid, and the transformation of the obtained base into an acid addition salt.

6. Process for the preparation of (R)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and (S)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, and their acid addition salts, comprising

- 5       a) the diazotation of (R)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine or (S)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine by reacting with an alkali-nitrite in the presence of hydrochloric acid, or
- 10       b) the resolution of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine, and the diazotation of the obtained optically active (R)-(-) enantiomer or (S)-(+) enantiomer in the presence of hydrochloric acid by reacting with an alkali-nitrite, or
- 15       c) the diazotation of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxamidine in the presence of hydrochloric acid by reacting with an alkali-nitrite, and the isolation of the required (R)-(+) or (S)-(-) enantiomer by resolving from the obtained raceme N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, or
- 20       e) the transformation of (R)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride or (S)-(-)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, prepared by any of the process variants under a)-c), into an acid addition salt.

7. N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride and its acid addition salts prepared by the process as claimed in claim 5
8. (R)-(+)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride and its acid addition salts prepared by the process as claimed in claim 6.
9. (S)-(-)-(N)-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl-chloride and its acid addition salts prepared by the process as claimed in claim 6.






Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/HU 01/00046

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D213/89

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 00 50403 A (KUERTHY, M. ET AL.) 31 August 2000 (2000-08-31) cited in the application Abstract; claims 1-7; example 1 (= present compd. V); examples 2 and 3 (= enantiomers of present compd. V).	7-9
A	US 5 147 879 A (NAGY, P. L. ET AL.) 15 September 1992 (1992-09-15) Abstract; example 2; example 5, and column 2, lines 43-50.	1-9
A	US 5 296 606 A (NAGY, P. L. ET AL.) 22 March 1994 (1994-03-22) Abstract; example 2; example 5; and column 2, line 65 to column 3, line 4.	1-9
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

12 July 2001

Date of mailing of the international search report

19/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Weisbrod, T

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/HU 01/00046

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 16439 A (HEGEDUES, E. ET AL.)            9 May 1997 (1997-05-09)            cited in the application            Claims; page 49-50, examples 14 and 15.</p>	7-9

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 01/00046

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0050403 A	31-08-2000	AU 3182400 A	14-09-2000
US 5147879 A	15-09-1992	HU 54110 A	28-01-1991
		AT 102603 T	15-03-1994
		AU 620460 B	20-02-1992
		AU 4418689 A	14-05-1990
		CA 2000830 A,C	20-04-1990
		DE 68913737 D	14-04-1994
		DE 68913737 T	28-07-1994
		DK 149790 A	19-06-1990
		EP 0417210 A	20-03-1991
		ES 2020030 A	16-07-1991
		FI 93214 B	30-11-1994
		GR 89100669 A,B	29-11-1990
		WO 9004584 A	03-05-1990
		HU 9500117 A	28-06-1995
		IE 65113 B	04-10-1995
		IL 92000 A	24-06-1994
		JP 8019078 B	28-02-1996
		JP 3502931 T	04-07-1991
		KR 154117 B	01-12-1998
		NO 178148 B	23-10-1995
		PL 164547 B	31-08-1994
		PT 92041 A,B	30-04-1990
		RU 2093508 C	20-10-1997
		US 5328906 A	12-07-1994
		US 5296606 A	22-03-1994
US 5296606 A	22-03-1994	HU 54110 A	28-01-1991
		US 5328906 A	12-07-1994
		AT 102603 T	15-03-1994
		AU 620460 B	20-02-1992
		AU 4418689 A	14-05-1990
		CA 2000830 A,C	20-04-1990
		DE 68913737 D	14-04-1994
		DE 68913737 T	28-07-1994
		DK 149790 A	19-06-1990
		EP 0417210 A	20-03-1991
		ES 2020030 A	16-07-1991
		FI 93214 B	30-11-1994
		GR 89100669 A,B	29-11-1990
		WO 9004584 A	03-05-1990
		HU 9500117 A	28-06-1995
		IE 65113 B	04-10-1995
		IL 92000 A	24-06-1994
		JP 8019078 B	28-02-1996
		JP 3502931 T	04-07-1991
		KR 154117 B	01-12-1998
		NO 178148 B	23-10-1995
		PL 164547 B	31-08-1994
		PT 92041 A,B	30-04-1990
		RU 2093508 C	20-10-1997
		US 5147879 A	15-09-1992
WO 9716439 A	09-05-1997	HU 76659 A	28-10-1997
		AU 720195 B	25-05-2000
		AU 7326396 A	22-05-1997
		BG 101713 A	31-03-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HU 01/00046

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9716439 A		BR 9607565 A	20-07-1999
		CA 2209167 A	09-05-1997
		CN 1177351 A	25-03-1998
		CZ 9702072 A	18-03-1998
		EP 0801649 A	22-10-1997
		HR 960508 A	30-06-1998
		JP 10512590 T	02-12-1998
		NO 973059 A	02-09-1997
		PL 322015 A	05-01-1998
		SK 88197 A	08-04-1998
		TR 9700574 T	23-08-1999